International Drug Development Institute (Belgium) View Homepage


Ontology type: grid:Company  | foaf:Organization     


Organization Info

NAME

International Drug Development Institute (Belgium)

HOMEPAGE

http://www.iddi.com/

ADDRESS

http://www.grid.ac/institutes/grid.482598.a/address-0

Publications in SciGraph latest 20 shown

  • 2019-12 PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial in BREAST CANCER RESEARCH
  • 2017-12 Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40) in ALZHEIMER'S RESEARCH & THERAPY
  • 2017-07 Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors” in DRUGS
  • 2017-05 Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors in DRUGS
  • 2017-05 Precision medicine needs randomized clinical trials in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2016-12 Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab in CANCER COMMUNICATIONS
  • 2016-07 Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework in NATURE REVIEWS DRUG DISCOVERY
  • 2016-05 Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial in JOURNAL OF NEURO-ONCOLOGY
  • 2016-02 Data-driven risk identification in phase III clinical trials using central statistical monitoring in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2015-07 Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 in BREAST CANCER RESEARCH AND TREATMENT
  • 2015-03 Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer in BRITISH JOURNAL OF CANCER
  • 2015-01 Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study in BREAST CANCER RESEARCH AND TREATMENT
  • 2014 Estimation of Optimally Combined-Biomarker Accuracy in the Absence of a Gold Standard Reference Test in THE CONTRIBUTION OF YOUNG RESEARCHERS TO BAYESIAN STATISTICS
  • 2014 Implementation Issues in Adaptive Design Trials in PRACTICAL CONSIDERATIONS FOR ADAPTIVE TRIAL DESIGN AND IMPLEMENTATION
  • 2013-12 Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-10 Markers for nutrition studies: review of criteria for the evaluation of markers in EUROPEAN JOURNAL OF NUTRITION
  • 2013-02 Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-07 Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-06 Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial in BREAST CANCER RESEARCH
  • 2011-12 Statistical validation of surrogate outcome measures in TRIALS
  • JSON-LD is the canonical representation for SciGraph data.

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "foaf:homepage": [
          {
            "id": "http://www.iddi.com/"
          }
        ], 
        "grid:establishedYear": [
          {
            "@value": "1991-01-01", 
            "type": "http://www.w3.org/2001/XMLSchema#gYear"
          }
        ], 
        "grid:hasAddress": [
          {
            "id": "http://www.grid.ac/institutes/grid.482598.a/address-0"
          }
        ], 
        "grid:id": [
          {
            "@value": "grid.482598.a"
          }
        ], 
        "id": "http://www.grid.ac/institutes/grid.482598.a", 
        "rdfs:label": "International Drug Development Institute (Belgium)", 
        "sdDataset": "grid", 
        "skos:prefLabel": [
          {
            "@value": "International Drug Development Institute (Belgium)"
          }
        ], 
        "type": [
          "http://xmlns.com/foaf/0.1/Organization", 
          "http://www.grid.ac/ontology/Company"
        ], 
        "vivo:abbreviation": [
          {
            "@value": "IDDI"
          }
        ]
      }, 
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "geo-pos:lat": [
          {
            "@value": "50.658944", 
            "type": "http://www.w3.org/2001/XMLSchema#float"
          }
        ], 
        "geo-pos:long": [
          {
            "@value": "4.563025", 
            "type": "http://www.w3.org/2001/XMLSchema#float"
          }
        ], 
        "grid:cityName": [
          {
            "@value": "Brussels"
          }
        ], 
        "grid:countryCode": [
          {
            "@value": "BE"
          }
        ], 
        "grid:countryName": [
          {
            "@value": "Belgium"
          }
        ], 
        "grid:hasGeonamesCity": [
          {
            "id": "http://sws.geonames.org/2800866/"
          }
        ], 
        "id": "http://www.grid.ac/institutes/grid.482598.a/address-0", 
        "sdDataset": "grid", 
        "type": [
          "http://www.grid.ac/ontology/Address"
        ]
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://www.grid.ac/institutes/grid.482598.a'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://www.grid.ac/institutes/grid.482598.a'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://www.grid.ac/institutes/grid.482598.a'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://www.grid.ac/institutes/grid.482598.a'


     

    This table displays all metadata directly associated to this object as RDF triples.

    18 TRIPLES      9 PREDICATES      10 URIs      5 LITERALS

    Subject Predicate Object
    1 grid-institutes:grid.482598.a sgo:sdDataset grid
    2 vivo:abbreviation IDDI
    3 grid:establishedYear 1991-01-01
    4 grid:hasAddress grid-institutes:grid.482598.a/address-0
    5 grid:id grid.482598.a
    6 rdf:type grid:Company
    7 foaf:Organization
    8 rdfs:label International Drug Development Institute (Belgium)
    9 skos:prefLabel International Drug Development Institute (Belgium)
    10 foaf:homepage http://www.iddi.com/
    11 grid-institutes:grid.482598.a/address-0 sgo:sdDataset grid
    12 grid:cityName Brussels
    13 grid:countryCode BE
    14 grid:countryName Belgium
    15 grid:hasGeonamesCity http://sws.geonames.org/2800866/
    16 rdf:type grid:Address
    17 geo-pos:lat 50.658944
    18 geo-pos:long 4.563025
     




    Preview window. Press ESC to close (or click here)


    ...